Injectable “Mini Livers” Could Replace Transplants for Chronic Liver Disease

MIT Professor Sangeeta Bhatia and her colleagues have developed a technique that injects functioning liver cells into the body as a potential alternative to full organ transplantation. The approach pairs hepatocytes, the specialized cells responsible for most of the liver's critical functions, with hydrogel microspheres that hold the cells together and help them form connections with surrounding blood vessels. The target patients are the thousands of Americans living with chronic liver disease who are either waiting for a donor organ or are not healthy enough to survive transplant surgery.

<![CDATA[

What happened

Professor Sangeeta Bhatia (SM ’93, PhD ’97) at MIT has spent roughly a decade developing ways to restore liver function without surgically replacing the organ. Her latest work, covered by MIT Technology Review on June 23, 2026, centers on injecting hepatocytes directly into the body alongside hydrogel microspheres.

The microspheres serve two purposes: they keep the cells clustered together rather than dispersing, and they help the clusters form connections with nearby blood vessels. That vascular integration is critical. Without a blood supply, transplanted cells die before they can do anything useful.

Hepatocytes are the workhorses of the liver. According to the source, they are responsible for:

• Regulating blood clotting
• Removing bacteria from the bloodstream
• Metabolizing drugs and other compounds

Restoring even a portion of that function could make a meaningful difference for patients who currently have no good options.

Why it matters

Liver transplantation is the only proven cure for end-stage liver disease, but the supply of donor organs is far smaller than demand. Many patients die waiting. Others are too sick for surgery to be a realistic option at all.

A cell injection approach sidesteps the need for a full donor organ and, in theory, avoids the surgical trauma of an open transplant procedure. If the hepatocyte clusters can sustain themselves and expand their connection to the host’s blood supply over time, patients could see real functional improvement without ever going into an operating room for a major surgery.

The hydrogel microsphere component is the key engineering detail here. Getting cells to survive after injection has historically been the main obstacle to this kind of therapy. Bhatia’s lab appears to have found a structural scaffold that addresses that problem, at least in early testing.

Our take

This is genuinely interesting science, but it is worth being clear about where it sits on the road to clinical use. The source excerpt describes a technique developed in a research lab, not a treatment that has passed clinical trials or received regulatory approval. A decade of work from a serious research group is encouraging, not a guarantee of an approved therapy anytime soon.

The vascular integration piece is the detail we would watch most closely. Cell therapies for the liver have been attempted before, and the recurring failure mode is poor engraftment, meaning cells do not connect well enough to survive long-term. The hydrogel microsphere idea is a concrete attempt to solve that, and that specificity is what separates this from a lot of earlier work in the space.

For anyone following biotech or healthcare AI, this also connects to a broader pattern: researchers are increasingly using engineered materials alongside biological cells rather than treating them as separate fields. That combination is producing results that neither biology nor materials science alone could achieve.

What to do about it

If you work in healthcare communications, medical publishing, or biotech investment, keep an eye on publications from Bhatia’s lab at MIT for peer-reviewed data on engraftment rates and animal model outcomes. Those numbers will tell you how seriously to take the clinical timeline claims when they start appearing.

]]>

Source: MIT Technology Review